Item 8.01. Other Information" -->
Item 8.01. Other Information
The Company today released results from its one-year extension safety study of Proellex in the
chronic treatment of the symptoms associated with uterine fibroids.
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release
is incorporated by reference herein and the foregoing description of the press release is qualified
in its entirety by reference to the attached exhibit.
Item 9.01. Financial Statements and Exhibits
c. Exhibits
| Exhibit | ||
| Number | Description | |
99.1
|
Press Release dated May 29, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Repros Therapeutics Inc. |
||||
| Date: May 29, 2008 | By: | /s/ Louis Ploth, Jr. | ||
| Louis Ploth, Jr. | ||||
| Vice President, Business Development and Chief Financial Officer |
||||
EXHIBIT INDEX
| Exhibit | ||
| Number | Description | |
99.1
|
Press Release dated May 29, 2008 |